BC Week In Review | Jan 21, 2008
Clinical News

Asord becocalcidiol: Phase II started

CollaGenex began a U.S. Phase II trial to compare once-daily becocalcidiol to placebo and dovonex in 300 patients for 12 weeks. QuatRx granted CollaGenex exclusive rights outside of Japan for becocalcidiol to treat psoriasis and...
BioCentury | Jan 7, 2008

Selling out to reach the finish line

Investors in Hormos Medical Corp. decided in 2005 that they were better off putting the Finnish company's compounds in the hands of an acquirer with clinical development skills than getting more funding at a reduced...
BC Week In Review | May 21, 2007
Company News

CollaGenex, QuatRx deal

QuatRx granted CGPI exclusive, worldwide rights, excluding Japan, to develop and commercialize becocalcidiol to treat psoriasis and other skin diseases. The vitamin D analog ointment met the primary endpoint of clearing or almost clearing psoriatic...
BioCentury | Feb 13, 2006

Ebb & Flow

When OSI (OSIP) announced plans to buy Eyetech last year, angry shareholders took their pound of flesh by immediately driving the stock price down 22%. Their gripe was that they didn't think OSIP was buying...
BC Week In Review | Jun 20, 2005
Clinical News

Becocalcidiol: Phase IIb data

In a double-blind, vehicle-controlled, U.S. Phase IIb in 185 patients showed that both the high- and low-dose becocalcidiol met the primary endpoint compared with vehicle. More than 5 times the number of patients given high-dose...
BC Extra | Jun 15, 2005
Clinical News

QuatRx becocalcidiol Phase IIb psoriasis data

QuatRx (Ann Arbor, Mich.) said two doses of becocalcidiol ( QRX-101 ) met the primary endpoint of "clear" or "almost clear" of psoriatic lesions at eight weeks compared with vehicle in a Phase IIb trial to treat...
BioCentury | Dec 20, 2004

Vitamin D analog pipeline

Vitamin D analog pipeline Company Product Indication Status Abbott Zemplar Secondary hyperparathyroidism (SHPT) associated with chronic renal failure Mkt (IV form); capsule under review in U.S. Abbott Calcijex Hypocalcemia in patients undergoing chronic renal dialysis...
BC Extra | Dec 13, 2004
Financial News

QuatRx raises $31M

QuatRx (Ann Arbor, Mich.) raised $31 million in a venture round led by Thomas Weisel. Other investors included Frazier Healthcare; TL Ventures; MPM; InterWest; Stockwell Capital; and Twilight Ventures. Caley Castelein of Thomas Weisel and...
BioCentury | Mar 17, 2003
Tools & Techniques

Sizing up the psoriasis market

Company Compound Description Status Partner Biogen Amevive alefacept LFA-3 fusion protein Mkt Novartis Neoral cyclosporine Calcineurin inhibitor Mkt Genentech Raptiva efalizumab Anti-CD11a antibody Under review in U.S., Europe Serono; Xoma Allergan Tazorac tazarotene Oral retinoid...
BC Week In Review | Jan 27, 2003
Clinical News

QRX-101: Phase II

QuatRx started a U.S. Phase II dose-ranging study of QRX-101. The double-blind, placebo-controlled trial is expected to enroll 120 patients. QuatRx Pharmaceuticals Co. , Ann Arbor, Mich.   Product: QRX-101   Business: Autoimmune/Inflammation   Molecular target:...
Items per page:
1 - 10 of 11